MODIFICATION
B -- Large-Scale Genotyping for Population Based Studies on Cancer Susceptibility, Disease, and Treatment Response, for the National Cancer Institute Laboratory of Population Genetics
- Notice Date
- 10/9/2002
- Notice Type
- Modification
- Contracting Office
- Department of the Interior, Minerals Management Service, Procurement Operations Branch, MS2500, 381 Elden Street, Herndon, VA 20170-4817
- ZIP Code
- 20170-4817
- Solicitation Number
- 1435-04-03-RP-70022
- Response Due
- 11/4/2002
- Archive Date
- 11/4/2002
- Point of Contact
- Shanda Georg, Contract Administrator
- Description
- Below are Questions and responses in regards to the solicitation. Question 1 : We understand this solicitation is a RFP (mentioned in the beginning of the solicitation). But we are confused in the part of "E. Cost, Contract Award" (near the end of the solicitation) it says "..., in conforming to this RFQ,...". Is this solicitation a RFP or RFQ? Question 1 Government Response: This acquisition is in accordance with FAR 13.5 - Test Program for Certain Commercial Items. Simplified acquisition procedures are being used in accordance with FAR 13.5, therefore, this is an RFQ. The contractor shall provide a Technical proposal and a price quote. Question 2: Is this solicitation a small business set aside or not? Question 2 Government Response: This acquisition is not a small business set-aside. Question 3 : Is there a criterion that you based on to set the requirement for using 2 ng or less DNA per assay? In other words, which type of technology do you use in your studies to use 2 ng of DNA for the assay? Question 3 Government Response: For our present studies, we want to use less than 2 ng sample DNA per genotype. Our current technologies allow us to use from 0.25 ng to 2.0 ng DNA per genotype (MALDI-TOF, SNaPshot, and others). We are seeking technologies which either require less DNA per reaction or can reliably work in multiplexed reactions so that overall less DNA per genotype is consumed. Question 4 : Do you have any preference of using an existing SNP assay? Question 4 Government Response: If an existing assay can be proven to interrogate the specific SNP requested and passes our QC steps, then we will accept that assay for this contract. Question 5 : Is there a time line for the assay development for the first 25 SNPs? Question 5 Government Response: We would expect completion of the first 25 assays within 3 months of the beginning of the project initiation. We would be willing to negotiate somewhat on timing with the appropriate discussions. Question 6: Will all of the SNP assays established in phase 1 of this project be applied to phase 2 and phase 3 samples? Question 6 Government Response: Yes, all of the SNP assays established in phase 1 of this project are applied to phase 2 and phase 3 samples. Question 7: Will all of the desired SNPs to be analyzed for this contract be supplied to the contractor in electronic format at the same time, or at different times? Question 7Government Response: The majority of the assays will be supplied at one time but there will be other assay requests made during the contract period. Question 8: For cost estimation purposes, should we use 25 SNPs per sample, 50 SNPs per sample, or an intermediate number? Question 8 Government Response: For cost estimation purposed, the ideal would be to use the 25 for a 'low # estimate' and the 50 for a 'hi # estimate' to give an estimate with a low/high range. If that is not possible, then use the 50 for the estimate. Question 9: For cost estimation purposes, should we assume that all phases of the project will have the identical number of SNP analyses required for each sample? Question 9 Government Response: Yes, for cost estimation purposes, assume that all phases of the project will have the identical number of SNP analyses required for each sample. Question 10: For cost estimation purposes, should we include costing of the fourth and optional phase of 3000 clinical DNA samples, and would the number of SNPs required be identical to the assay quality control samples and the pilot clinical sample set? Question 10 Government Response: Yes, for cost estimation purposes, include costing of the fourth and optional phase of 3000 clinical DNA samples and the number of SNP analyses required for each sample will be the same as for the assay quality control samples and the pilot clinical samples. Question 11: Will the DNA which is provided to the contractor for SNP analyses be accurately quantitated? Government Response: The DNA provided to the contractor will be quantitated by a picogreen DNA quantification assay before shipment to the contractor. Question 12: Has any previous genotyping work been performed on the "variety of clinical samples" to be genotyped in this contract, which would have demonstrated that the quality of all (or at least 80%) of the samples is sufficient for genotyping analysis (i.e. the DNAs are not extensively degraded)? Question 12 Government Response: Yes, the clinical DNA samples will have been though our lab quality control process and generated previous genotyping data of sufficient quality to expect them to perform well in the assays for this contract.
- Record
- SN00185250-W 20021011/021009213429 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |